PATENT CLAIM ANALYSIS

Application Number: 16202210
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-03
Patent Classification: ["514", "230500"]

Abstract:
The present invention provides methods and uses of inhibitors of histone deacetylase 11 (HDAC11) in the treatment of diseases and/or disorders, such as, for example, cell proliferative diseases.

Claim (Index 15):
A method of treating a hematological cancer comprising administering to a patient an effective amount of a HDAC11 inhibitor.

Metadata:
- Claim Count in Document: 14.0
- Percentile: 98.0
- Lexical Diversity: 1.17241
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['16202207', '15234412', '13683880', '11687565', '14763013']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7489456845001762
- 35 USC 102 Novelty (BERT): 0.6003346480188347
- Combined Prediction Score: 0.734084580852042
- Mean Citation Score: 375.980184
- Max Citation Score: 624.77814
- Similarity Product: 412.3141519652939

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test